NCT06724848 A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Pre-COPD Outcomes in Chinese Population
| NCT ID | NCT06724848 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | COPD |
| Study Type | OBSERVATIONAL |
| Enrollment | 850 participants |
| Start Date | 2024-06-05 |
| Primary Completion | 2027-10-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 850 participants in total. It began in 2024-06-05 with a primary completion date of 2027-10-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational study into more comprehensive understanding, including the trajectories of lung function decline, inflammatory/immunological mechanisms on pre-COPD or PRISm, clinical outcomes and relevant endotypes on physician-diagnosed COPD. The sponsor will follow up all participants for 1-year period.
Eligibility Criteria
Inclusion Criteria: * Capable of giving signed ICF * Able to perform acceptable lung function testing for FEV1 according to American Thoracic Society and European Respiratory Society 2019 acceptability criteria. * Able and willing to comply with the requirements of the protocol including ability to read, write, be fluent in the translated language of all participants facing questionnaires used at center. * Participants will be allowed to enroll into other non-intervention studies while taking part in this study. Exclusion Criteria: * The participant has a history of alcohol or drug abuse within the past year, which, in the opinion of the responsible physician, contra-indicates their participation. * The participant has an altered mental status at the time of informed consent. * Clinically significant abnormal laboratory values available vital signs, ECG, or laboratory testing at the screening assessment that, which in the opinion of the investigator, could interfere with the objectives of the study or safety of the participant. -Current diagnosis of asthma. * Clinically important pulmonary disease. * COPD exacerbation, within 2 weeks prior to enrollment or during screening period. * History of partial or total lung resection (single lobe or segmentectomy is acceptable). Surgical or endoscopic (eg, valves) lung volume reduction within the 6 months prior to enrollment. Expected need for lung volume reduction surgery during the study. * Unstable disorders. * Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrollment. Suspected malignancy or undefined neoplasms. * Terminal disease and/or organ failure or participants otherwise considered not appropriate for the study participation. * Participants receipt marketed or investigational biologics biologics within 3 months or 5 half-lives prior to visit 1, whichever is longer. * Female participants who are pregnant.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06724848 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, studying COPD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06724848 currently recruiting?
Yes, NCT06724848 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT06724848 trial being conducted?
This trial is being conducted at Beijing, China, Changsha, China, Chengdu, China, Guangzhou, China and 10 additional locations.
Who is sponsoring the NCT06724848 clinical trial?
NCT06724848 is sponsored by AstraZeneca. The trial plans to enroll 850 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.